Keyword: Gritstone Oncology
After a year that saw biotech IPOs raise $6.3 billion and Moderna pull off a history-making $604 million listing, valuations may come down in 2019.
Gritstone Oncology has appointed Jonah Rainey, Ph.D., to head up its bispecific antibody program as it moves into lead optimization.
After raising more than $194 million in venture capital, Gritstone is looking to raise up to $80 million in its IPO.
The deal sees Bluebird pay $20 million upfront in return for 10 tumor-specific targets and T-cell receptors.
Gritstone Oncology and Bristol-Myers Squibb will start a phase 1 trial of a combination immunotherapy by year end.
Dominic Caruso retires as J&J's CFO, CVS hires ex-Lilly CFO Rice as the president of its PBM unit, former FDA informatics chief Kass-Hout joins Amazon.
NICE leader joined ABPI; Heptares co-founder will lead Merck’s new London center; Sanofi named a business transformation head.
Our panel discussed the meaning of good science and how different players can work together to leverage their respective strengths.
After getting off a $102 million series A, Gritstone Oncology has followed up with an impressive $92.7 million second round.
Gristone Oncology, a biotech-medtech crossover, is working to apply next-generation sequencing, bioinformatics and algorithms to the creation of new cancer immunotherapies.